2012Journal of Cutaneous Medicine and SurgeryRequires access

Efficacy of Topical Calcineurin Inhibitors in Lichen Planus

Michael Samycia, Andrew N. Lin

Open publisher page 36 citations

Abstract

BACKGROUND: Topical calcineurin inhibitors have been studied in many skin disorders, including lichen planus. OBJECTIVE: To evaluate published reports of the use of topical calcineurin inhibitors in lichen planus. METHODS: We searched PubMed, Ovid/Cochrane, and Embase using the keywords "tacrolimus," "pimecrolimus," "topical calcineurin inhibitors," and "lichen planus. " RESULTS: We examined 5 double-blind studies, 1 investigator-blinded study, 10 open prospective studies, 6 retrospective studies, and 28 case reports evaluating tacrolimus or pimecrolimus for oral, vulvovaginal, and cutaneous lichen planus. CONCLUSIONS: Strong evidence (double-blind and open studies) supports the use of topical tacrolimus ointment in oral lichen planus, with efficacy at least equal to topical clobetasol propionate 0.05% ointment. Treatment of oral lichen planus with topical tacrolimus ointment can result in demonstrable blood tacrolimus levels, but without clinically significant adverse events. Strong evidence (double-blind and open studies) supports the use of topical pimecrolimus 1% cream in oral lichen planus, with efficacy equal to that of topical triamcinolone acetonide 0.1% paste. For vulvovaginal lichen planus, pimecrolimus was superior to placebo in one double-blind study, and tacrolimus was effective in open studies. Only case reports support the efficacy of topical calcineurin inhibitors in cutaneous lichen planus.

About this research paper

What this paper is about

BACKGROUND: Topical calcineurin inhibitors have been studied in many skin disorders, including lichen planus. OBJECTIVE: To evaluate published reports of the use of topical calcineurin inhibitors in lichen planus. METHODS: We searched PubMed, Ovid/Cochrane, and Embase using the keywords "tacrolimus," "pimecrolimus," "topical calcineurin inhibitors," and "lichen planus. " RESULTS: We examined 5 double-blind studies, 1 investigator-blinded study, 10 open prospective studies, 6 retrospective studies, and 28 case reports evaluating tacrolimus or pimecrolimus for oral, vulvovaginal, and cutaneous lichen planus. CONCLUSIONS: Strong evidence (double-blind and open studies) supports the use of topical tacrolimus ointment in oral lichen planus, with efficacy at least equal to topical clobetasol propionate 0.05% ointment. Treatment of oral lichen planus with topical tacrolimus ointment can result in demonstrable blood tacrolimus levels, but without clinically significant adverse events. Strong evidence (double-blind and open studies) supports the use of topical pimecrolimus 1% cream in oral lichen planus, with efficacy equal to that of topical triamcinolone acetonide 0.1% paste. For vulvovaginal lichen planus, pimecrolimus was superior to placebo in one double-blind study, and tacrolimus was effective in open studies. Only case reports support the efficacy of topical calcineurin inhibitors in cutaneous lichen planus.

Why it matters

OpenAlex reports 36 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

BACKGROUND: Topical calcineurin inhibitors have been studied in many skin disorders, including lichen planus. OBJECTIVE: To evaluate published reports of the use of topical calcineurin inhibitors in lichen planus. METHODS: We searched PubMed, Ovid/Cochrane, and Embase using the keywords "tacrolimus," "pimecrolimus," "topical calcineurin inhibitors," and "lichen planus. " RESULTS: We examined 5 double-blind studies, 1 investigator-blinded study, 10 open prospective studies, 6 retrospective studies, and 28 case reports evaluating tacrolimus or pimecrolimus for oral, vulvovaginal, and cutaneous lichen planus. CONCLUSIONS: Strong evidence (double-blind and open studies) supports the use of topical tacrolimus ointment in oral lichen planus, with efficacy at least equal to topical clobetasol propionate 0.05% ointment. Treatment of oral lichen planus with topical tacrolimus ointment can result in demonstrable blood tacrolimus levels, but without clinically significant adverse events. Strong evidence (double-blind and open studies) supports the use of topical pimecrolimus 1% cream in oral lichen planus, with efficacy equal to that of topical triamcinolone acetonide 0.1% paste. For vulvovaginal lichen planus, pimecrolimus was superior to placebo in one double-blind study, and tacrolimus was effective in open studies. Only case reports support the efficacy of topical calcineurin inhibitors in cutaneous lichen planus.

Key concepts: Pimecrolimus, Tacrolimus, Medicine, Dermatology, Calcineurin, Oral lichen planus, Triamcinolone acetonide, Topical steroid

Related papers

Back to paper searchBrowse research topicsOriginal source
Efficacy of Topical Calcineurin Inhibitors in Lichen Planus — Research Paper | ScholarLens